Table 3.
Efficacy of antiviral prophylaxis in HBsAg-positive patients
| Events | No. (%) of patients | Difference between groups, % (95% CI) | OR (95% CI) | P valuea | ||
|---|---|---|---|---|---|---|
| Total (n = 114) | Patients without antiviral prophylaxis (n = 29) | Patients with antiviral prophylaxis (n = 85) | ||||
| Hepatitis | ||||||
| All grades | 35 (30.7) | 8 (27.6) | 27 (31.8) | 4.2 (−16.01–20.83) | 0.82 (0.32–2.08) | 0.674 |
| Grade 3/4 | 10 (8.8) | 4 (13.8) | 6 (7.1) | 6.7 (−4.50–23.89) | 2.10 (0.55–8.07) | 0.467 |
| HBV reactivation | 6 (5.3) | 5 (17.2) | 1 (1.2) | 16.0 (5.05–33.33) | 17.50 (1.95–157.07) | 0.004 |
| HBV-related hepatitis | 5 (4.4) | 4 (13.8) | 1 (1.2) | 12.6 (2.80–29.40) | 13.44 (1.44–152.79) | 0.019 |
| Immunotherapy disruptionb | 11 (9.6) | 4 (13.8) | 7 (8.2) | 5.6 (−5.78–22.88) | 1.78 (0.48–6.60) | 0.609 |
aDetermined using the χ2 test
bIncluded ten cases of immunotherapy delay and one case of discontinuation
Abbreviations: HBsAg hepatitis B surface antigen, HBV hepatitis B virus, OR odds ratio, CI confidence interval